Table 3.
Characteristics of Treated Patients.
| Study ID | Malignancy | N | Sex (% M) | Median age (range) | Prior CD19 CAR T-cells | Other prior therapy | |
|---|---|---|---|---|---|---|---|
| CD22 | |||||||
| Pan 2019 | ALL | 34 | 59% | 10 (1-55) | 31/34 | Allo-HCT: 13/34 | |
| Shah 2020 | ALL | 58 | NR | 17.5 (4.4-30.6) | 36/58 | CD22 CAR T cells: 5/58 Inotuzumab: 14/58 CD19-targeted therapy: 51/58 Blinatumomab: 23/58 HCT: 39/58 |
|
| Singh 2021 | ALL | 8 | NR | NR; 3 adults, 5 pediatrics | 5/8 | Prior allo-HSCT: 3/8 Blinatumomab: 3/8 |
|
| Summers 2021 | V1 | ALL | 4 | NR | NR | NR | NR |
| V2 | ALL | 3 | NR | NR | 3/3 | NR | |
| Tan 2021 | ALL | 8 | 25% | 9 (5-16) | NR | Prior CD19 and CD22 directed therapies: 8/8 Prior allo-HSCT: 4/8 |
|
| Zhu 2021 | ALL | 6 | 50% | 39.5 (25-58) | 13/13 | NR | |
| DLBCL | 7 | 71% | 56 (16-70) | ||||
| Baird 2021 | LBCL | 21 | 62% | 64 (36-79) | 20/21 | Allo-SCT: 6/21 | |
| CD19/CD22 | |||||||
| Annesley 2021 | ALL | 11 | NR | NR | 4/11 | CD19 or CD22 targeted therapies: 11/12 enrolled pts | |
| Cordoba 2021 | ALL | 15 | 73% | 8 (4-16) | 1/15 | Allo-SCT: 7/15 | |
| Dai 2020 | ALL | 6 | 67% | 23.5 (17-44) | NR | NR | |
| Frey 2021 | ALL | 13 | NR | 46 (28-71) | 2/13 | Blinatumomab: 8/13 Inotuzumab: 8/13 Prior allogeneic SCT: 10/13 |
|
| Gardner 2020 | ALL | 27 | NR | NR | NR | CD19 or CD22 targeted therapies: 13/27 | |
| Hu 2021 | ALL | 6 | 33% | 49 (26-56) | NR | NR | |
| Liu 2021 A | ALL | 27 | 52% | 21 (1.6–55) | NR | All had relapsed post allo-HCT | |
| Liu 2021 B | Tandem | ALL | 49 | NR | NR | NR | NR |
| Sequential | ALL | 13 | NR | NR | NR | ||
| Pan 2020 | ALL | 20 | 65% | 6 (1-16) | NR | NR | |
| Schultz 2018 | ALL | 4 | NR | NR (2-17) | NR | NR | |
| Shalabi 2020 | ALL | 11 | NR | 21 (5-28) | 5/11 | NR | |
| Speigel 2021 | ALL | 17 | 71% | 47 (26-68) | 1/17 | Allo-SCT: 12/17 | |
| LBCL | 21 | 67% | 69 (25-78) | NR | Auto-SCT: 4/21 | ||
| Wang 2020 | ALL | 51 | 63% | 27 (9-62) | NR | Allo-HCT: 9/51 Auto-HCT: 3/51 |
|
| NHL | 38 | 58% | 47 (17-11) | NR | Auto-HCT: 6/38 | ||
| Wang 2021 | TCF3-HLF+ALL | 4 | 100% | 6.8 (2.9-14.7) | NR | NR | |
| Wei 2021 | ALL | 15 | 47% | 27 (16-65) | 0/15 | Prior HSCT: 1/15 | |
| NHL | 16 | 50% | 52.5 (23-68) | 0/16 | Auto-HSCT: 1/16 | ||
| Yang 2018 | ALL | 15 | 73% | 19 (4-45) | NR | NR | |
| Yang 2020 | ALL | 10 | 50% | 11.5 (3-48)† | 3/10 | Allo-HSCT: 1/10 | |
| Yang 2019 | ALL | 16 | 59% | 8 (4-45) | 4/17 | NR | |
| Cao 2021 | Aggressive NHL | 42 | 57% | 41 (24-61) | NR | No prior HSCT | |
| Liu 2022 | Burkitt | 23 | NR | 8 (2-12) | NR | NR | |
| Ramakrishnan 2020 | DLBCL | 19 | NR | 57 (28-71) | 0/19 | No prior CD19 or CD22-directed therapies or allo-HCT | |
| Zhang 2021 A | NHL | 32 | 59% | NR | 0/32 | Prior HSCT: 4/32 | |
| Zhang 2021 B | NHL | 11 | NR | NR | NR | NR | |
NR, not reported.